Shilpa Medicare Stock Price - ₹956.15 | Healthcare

‌
‌
‌

Company insights, generated from the most recent coverage.

US revenue grew 67% YoY to ₹80 Cr in FY26; profit-sharing model with US partner buffers against direct recall costs for specific batches.
Read more
Voluntary Class II recall of 27,923 Pemetrexed vials due to discoloration has no material financial impact as per company; zero adverse events reported.
Read more
Proactive voluntary recall demonstrates strong quality control commitment, potentially strengthening regulatory standing despite minor batch issue.
Read more

‌
‌
‌

The Quarter story

The two most recent quarterly results, compared side-by-side.

Profitability surges on strong formulations growth, while rising operational costs and regional revenue shifts require attention.

Adjusted PAT grew from ₹55 Cr to ₹101 Cr from Q3 FY26 to Q1 FY27, showing strong profit leverage.

Europe revenue dropped from ₹73 Cr to ₹57 Cr from Q3 FY26 to Q1 FY27, indicating regional demand softness.

Formulations revenue more than doubled from ₹98 Cr to ₹198 Cr from Q1 FY26 to Q1 FY27, becoming a core growth driver.

Employee cost rose from ₹82 Cr to ₹100 Cr from Q1 FY26 to Q1 FY27, adding pressure on operating expenses.

US revenue surged from ₹28 Cr to ₹45 Cr from Q3 FY26 to Q1 FY27, expanding the company's high-value market share.

Other expenses increased from ₹68 Cr to ₹95 Cr from Q1 FY26 to Q1 FY27, requiring closer monitoring to protect margins.

EBITDA climbed from ₹98 Cr to ₹139 Cr from Q1 FY26 to Q1 FY27, reflecting improved operational efficiency.

Oncology API revenue fell from ₹141 Cr to ₹97 Cr from Q2 FY26 to Q4 FY26, signaling therapeutic segment headwinds.

Adjusted PAT margin expanded from 13% to 22% from Q3 FY26 to Q1 FY27, confirming better cost control relative to sales.

Depreciation charges climbed from ₹29 Cr to ₹35 Cr from Q1 FY26 to Q1 FY27, reflecting higher asset base costs.

‌
‌
‌

In the news

Shilpa Medicare recalls 27,923 chemotherapy vials in US

Shilpa Medicare Q4 FY26 Results: Record ₹466 cr revenue, dividend record date set

Shilpa Medicare enters monetisation phase after ₹1,600 crore R&D spend

Shilpa Biologicals partners with Orion for IV nivolumab biosimilar

Raja Venkatraman Recommends 5 Stocks for June 3 Trading

5 Low-Risk Pharma Stocks for 2026: Healthcare Screener Analysis

Vaibhav Global Q4 PAT surges 167% YoY to ₹91 crore

Lupin Delivers Stellar Q4 Turnaround with 89% Profit Surge

NCLT approves Shilpa Medicare-Shilpa Therapeutics merger

Shilpa Medicare arm signs Latin America biosimilar deal

Shilpa Medicare shares jump 3% on NXI Therapeutics binding deal

Shilpa Medicare signs NCE development deal with NXI Therapeutics AG

Shilpa Medicare arm secures USFDA orphan drug tag for rare blood cancer biologic

Shilpa Medicare